Epitomics and Genentech extend Service and Licensing Agreement
Burlingame, CA - August 9, 2007
Service and License Agreement Update
Epitomics, Inc. has extended its current Service Agreement with Genentech, Inc. Under this Agreement, Genentech has agreed to service terms and diagnostic and therapeutic commercial terms for rabbit monoclonal antibodies produced under contract by Epitomics.
"We are delighted in expanding our relationship with such a respected and cutting edge biotechnology company as Genentech. The biotechnology and pharmaceutical markets are quickly adopting rabbit monoclonal antibodies (RabMabs) for such applications as drug discovery research, biomarker development and therapeutic applications. RabMabs' high affinity and greater diversity of antibodies gives superior performance over traditional antibodies", said Dr. Guo-Liang Yu, Chief Executive Officer of Epitomics, Inc.
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. (www.epitomics.com) is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.